Evommune, Inc.

EVMN · NYSE · Healthcare / Biotechnology

7.63USD-0.39 (-4.86%)

Price History

Full chart

Market Stats

Previous Close8.02

Open8.18

Day Range7.45 – 8.20

52-Week Range8.25 – 33.20

Volume722.97K

Market Cap319.37M

P/E (TTM)0.00

Forward P/E0.00

EPS-11.87

Dividend Yield0.00%

50-Day Avg12.19

200-Day Avg19.33

About

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Luis C. Pena
Employees48
Headquarters1891 Page Mill Road, Palo Alto, CA, United States, 94304, USA
Websitehttps://www.evommune.com

Leadership

Mr. Luis C. PenaFounder, President, CEO & Director · b. 1963
Mr. Kyle Carver CPA, M.B.A.Chief Financial Officer · b. 1988
Mr. Gregory S. Moss Esq.Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer · b. 1984
Dr. Eugene Andrew Bauer M.D.Co-Founder, Chief Medical Officer & Director · b. 1942
Dr. Jeegar Patel Ph.D.Chief Scientific Officer · b. 1978
Ms. Janice Drew M.P.H.Chief of Development Operations · b. 1963
Dr. Lou Sehl Ph.D.Senior Vice President of Technical Operations
Dr. Daniel J. Burge M.d.Senior Vice President of Clinical Development · b. 1962
Mr. J. Mark Jackson M.D.Senior Vice President of Clinical Development

Financials

Income Statement

Currency: USD	2023-12-31	2024-12-31	2025-12-31
Total Revenue	5.00M	7.00M	13.00M
Growth (%)	-	+40.00%	+85.71%
Cost of Revenue	1.00M	1.29M	1.39M
Gross Profit	4.00M	5.71M	13.00M
Gross Margin	80.00%	81.61%	100.00%
Operating Expense	41.85M	75.73M	94.07M
Operating Income	-37.85M	-70.01M	-81.07M
Operating Margin	-757.00%	-1000.19%	-623.62%
EBITDA	-32.99M	-65.49M	-67.48M
EBITDA Margin	-659.90%	-935.53%	-519.08%
Net Income	-34.05M	-66.81M	-68.87M
Net Income Margin	-681.06%	-954.40%	-529.77%
R&D	32.00M	64.24M	74.04M
R&D as % of Total Revenue	639.94%	917.77%	569.55%
Interest Expense	58.00K	34.00K	7.00K
Interest Expense % of Total Revenue	1.16%	0.49%	0.05%

Balance Sheet

Currency: USD	2023-12-31	2024-12-31	2025-12-31
Total Assets	82.25M	76.06M	224.95M
Total Liabilities	159.96M	220.29M	19.38M
Total Equity	-77.71M	-144.24M	205.57M
Cash	29.02M	16.25M	44.06M
Total Debt	150.63M	193.31M	2.06M
Net Debt	121.61M	177.06M	-42.00M

Cash Flow

Currency: USD	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-29.97M	-58.20M	-76.44M
Investing Cash Flow	-48.43M	-3.99M	-115.31M
Financing Cash Flow	63.75M	49.42M	220.76M
Capital Expenditure	118.00K	88.00K	235.00K
Free Cash Flow	-30.09M	-58.28M	-76.68M
FCF to OCF	100.39%	100.15%	100.31%

Earnings

Report Date	Dec 11, 2025	Mar 5, 2026	May 8, 2026	Aug 6, 2026
EPS Estimate	-11.35	-0.84	-0.85	-0.68
EPS Actual	-8.07	-1.43	-0.64	-0.89
Surprise	28.90%	-70.24%	24.05%	-30.88%
Timing	After-hours	After-hours	-	After-hours

Key Statistics & Ratios

Market Cap319.37M

Enterprise Value125.60M

Trailing P/E0.00

Forward P/E0.00

Price / Sales31.94

Price / Book1.15

EPS-11.87

Book Value7.65

Revenue (TTM)10.00M

Gross Profit (TTM)10.00M

EBITDA-100.36M

Profit Margin0.00%

Operating Margin-1018.94%

Return on Equity-52.11%

Return on Assets-31.99%

Shares Outstanding36.29M

Shares Float19.88M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Ownership Breakdown

Institutions: 114.68%
Insiders: 3.15%
Retail / Other: 0.00%

Top Institutional Holders

EQT Fund Management S.à r.l.
5.29M14.57%
RA Capital Management, LLC
3.49M9.63%
Pivotal bioVenture Partners Investment Advisor LLC
1.93M5.31%
RTW INVESTMENTS, LLC
1.50M4.14%
JPMorgan Chase & Co
1.46M4.02%
Nan Fung Group Holdings Ltd
1.44M3.97%
Andera Partners
1.39M3.84%
SymBiosis Capital Partners, LLC
1.28M3.53%
Eventide Asset Management, LLC
1.21M3.33%
T. Rowe Price Associates, Inc.
1.12M3.08%
HHG PLC
896.70K2.47%
Marshall Wace Asset Management Ltd
879.73K2.42%
Baker Bros Advisors LP
847.39K2.33%
Defilade Capital Management, L.P.
793.14K2.19%
American Century Companies Inc
755.02K2.08%
Alyeska Investment Group, L.P.
726.36K2.00%
BlackRock Inc
673.57K1.86%

Top Fund Holders

Eventide Healthcare & Life Sciences I
1.21M3.33%
Vanguard MStar Total Stk Mkt Idx Invest
739.07K2.04%
T. Rowe Price New Horizons
582.72K1.61%